Host: Jennifer Caudle, DO

Guest: Sandra P. Reyna, MD

Spinal muscular atrophy (SMA) is a challenging rare disease that requires a diagnosis and access to treatment as early as possible. To help us understand the importance of early treatment, Dr. Sandra Reyna from Novartis Gene Therapies shares key considerations for optimizing outcomes and gives us some insight into available SMA treatment options, focusing on the gene therapy ZOLGENSMA.

© 2022 Novartis Gene Therapies, Inc.
US-ZOL-22-0129 08/22